



Intensifying the application of alternative methods in the development of cosmetic projects Márcio Lorencini, PhD Products Evaluation and Regulatory Affairs Manager

Safety and efficacy evaluation of cosmetics



Safety and efficacy evaluation of cosmetics



Safety and efficacy evaluation of cosmetics

 Grupo Boticário does not use animal tests for final products evaluation since 2000


 We do not use cosmetic ingredients that were tested in animals according to European ban (2009/2013)

 We study and develop different alternative methods



Safety and efficacy evaluation of cosmetics

3D Skin







Organs-on-chip

Safety and efficacy evaluation of cosmetics

The importance of alternative methods


- Preclinical safety assessment
- Optimization of clinical phase
- Reliability and velocity for the process of product development



 New research projects with focus on efficacy evaluation and design of innovative benefits (including the elucidation of mechanisms of action)

Safety and efficacy evaluation of cosmetics

The application of alternative methods in the different steps of cosmetics development



The (r)evolution of alternative methods

From the restriction in the use of animals according to the 3Rs concept: Reduction Refinement Replacement

For the expansion of analyses with the application of different methodologies

The (r)evolution of alternative methods

From the restriction in the use of animals according to the 3Rs concept: Reduction Refinement Replacement

For the expansion of analyses with the application of different methodologies


1) Different biological models

2) Different techniques of analyses

The (r)evolution of alternative methods

Animal *in vivo* models

Human in vitro models










Human but NOT SYSTEMIC


The (r)evolution of alternative methods

Human-based models are attractive, but they might evolve...



The (r)evolution of alternative methods


Organs on chips as the next step of human cell cultures...



The (r)evolution of alternative methods

Human on a chip!





Adapted from Marx et al. ATLA 42, 2012

Technical considerations

How to address each question to the right model?



- Complexity is not always an advantage
- Sometimes we want to look at biological interactions, sometimes not
- The model must be in accordance with the techniques that will be used for the analyses

Technical considerations

Possibility of working with different techniques

• Light and fluorescence microscopy


- Flow cytometry
 - ELISA
- 2D electrophoresis
- Southern, Northern and Western blot

• PCR

- Microarray
- DNA sequencing
 - Bioinformatics


Technical considerations

Evolution of biomolecular complexity



Technical considerations

Omics approaches



J Invest Dermatol. 2005 Apr;124(4):viii-x.

Skinomics.

Blumenberg M.

Examples

Improvement of methods for the evaluation of cytotoxicity

Toxicol In Vitro. 2012 Aug 28. pii: S0887-2333(12)00226-3. doi: 10.1016/j.tiv.2012.08.019. [Epub ahead of print]

A label-free, impedance-based real time assay to identify drug-induced toxicities and differentiate cytostatic from cytotoxic effects.

Kustermann S, Boess F, Buness A, Schmitz M, Watzele M, Weiser T, Singer T, Suter L, Roth A.

PLoS One. 2012;7(11):e50607. doi: 10.1371/journal.pone.0050607. Epub 2012 Nov 21.

Titanium Dioxide (TiO(2)) Nanoparticles Preferentially Induce Cell Death in Transformed Cells in a Bak/Bax-Independent Fashion.

Zhu Y, Eaton JW, Li C.

Exp Dermatol. 2012 May;21(5):370-5. doi: 10.1111/j.1600-0625.2012.01479.x.

Quercetin enhancement of arsenic-induced apoptosis via stimulating ROS-dependent p53 protein ubiquitination in human HaCaT keratinocytes.

Shen SC, Lee WR, Yang LY, Tsai HH, Yang LL, Chen YC.


Int J Cosmet Sci. 2012 Apr;34(2):176-82. doi: 10.1111/j.1468-2494.2011.00698.x. Epub 2011 Dec 30.

In vitro induction of apoptosis, necrosis and genotoxicity by cosmetic preservatives: application of flow cytometry as a complementary analysis by NRU.

Carvalho CM, Menezes PF, Letenski GC, Praes CE, Feferman IH, Lorencini M.

Examples

Evaluation of epidermal markers using 3D skin model



Examples

Safety assessment of cosmetic preservatives

SAFETY ASSESSMENT OF COSMETIC PRESERVATIVES

CANAVEZ A.D.P.M., BROHEM C.A., LORENCINI M.

epartment of Safety and Efficacy Assessment, Boticario Group

INTRODUCTION

Consumers are seeking products developed with attentive to the potential health hazards of ingredients. Preservatives are important to prevent microbial growth, however some aspects must be considered for a complete risk assessment, such as concentration limits defined by legislation, toxicological concerns depending on exposure, and the potential to cause adverse reaction according to scientific literature. In USA, women use an average of 12 personal care products a day, which generates an aggregate exposure that should be considered for effective formulations.

OBJECTIVE

The aim of this study was to develop a matrix of preservative toxicology to indicate safe limits according to each product's category.

METHODOLOGY

The rationale was based on a comparative hazard and risk/exposure assessment for 14 preservatives commonly used in cosmetics, considering available results from in silico, in vitro, clinical, and epidemiological studies. Aggregate exposure was also evaluated for finished products. Two correlated dimensions composed the toxicological matrix: 1) local or systemic exposure, considering the endpoints skin sensitization and irritation, eye irritation, phototoxicity, and 2) toxicity level, defined as low, moderate, or high in accordance with the main toxicological guidelines.

Risk assessment considered the margin of safety (MoS) and estimated exposure, with basis on concentration, frequency of use, route, and target population such as children, pregnant, or sensitive skin. Aggregate exposure was calculated for a complete product line, considering combined and sequential use of cosmetics. Risk and hazard assessments generated threshold recommendations for the application of preservatives in different cosmetic categories.



		-			-								
CAS	INGREDIENTS	HAZARD ASSESSMENT LOCAL AND SYSTEMIC EXPOSURE							RISK ASSESSMENT				
		skin sensitization	skin irritation	eye irritation	phototoxicity	Acute oral toxicity	carcinogenicity	mutagenicity	reproductive toxicity	NOAEL repeated dose oral toxicity studies mg/kg bw/d	maximum concentratio n allowed by EU legislation or usual concentratio n	SED (mg/kg bw/day)	MoS (margir of safety)
100-51-6	BENZYL ALCOHOL	H	L	н	L	M	L	L	L	500	0,60	1,614	309,7893432
26172-55-4	METHYLISOTHIAZOLINONE (MIT) E METHYLCHLOROISOTHIAZOLINONE (CMIT)	н	н	н	i.		L	ι	L	2,8	0,001500	0,004035	693,9281289
61789-71-7	BENZALKONIUM CHLORIDE	M	M	н	N/A	н	L	L	L	82	0,10	0,269	304,8327138
122-99-6	PHENOXYETHANOL	8	8	H	B	M	L	L	L	357	1,00	2,69	132,7137546
1117-86-8	CAPRYLYL GLYCOL	8	8	H	B	B	L	L	L	300	0,50	1,345	223,0483271
532-32-1	SODIUM BENZOATE	8	8	M	B	B	L	L	L	1000	0,50	1,345	743,4944238
24634-61-5	POTASSIUM SORBATE	8	8	н	в	В	L	L	L	1000	0,60	1,614	619,5786865
70445-33-9	ETHYLHEXYLGLYCERIN	7.1	B	н	8	M	L	L	EV8	800	1,00	2,69	297,3977699
55406-53-6	IODOPROPYNYL BUTYLCARBAMATE	н	в	н	8	н	L	L	M	20	0,01	0,0269	743,4944238
2682-20-4	METHYLISOTHIAZOLINONE	H	н	н	В	н	L	L	L	19	0,01	0,0269	706,3197026
	DEHYDROACETIC ACID/ SODIUM DEHYDROACETATE	L	L	M	в	н	L	L	L	100	0,01	0,01614	6195,786865
104-29-0	CHLORPHENESIN	L	a.	M	в	L	L	$\langle \mathbf{L} \rangle$	L	100	0,30	0,807	123,9157373
90-80-2	GLUCONOLACTONE	L	L	L	N/A	L	L	L	L	594	0,70	1,883	315,4540627
60177-36-8	SORBITAN CAPRYLATE	L .	L	L	N/A	L	L	L	L.	1000	1.00	2.69	371,7472115

Margin of safety was calculated by use of the following equation NOAEUSED to each ingredient. Dermal Absorption was assumed a 100% considering the worst-case scenario and relative daily exposure was considered 268 mg/kg bw/day According, SCCS Notes Of Collidance For The Testing Of Costmetic Ingredients And Their Safety Evaluation 9th Arevina, 2015. This calculation allows to extrapolate from a group of test animals to an average human population. A default value of 100 (10x10) is generally accepted and a NoS of at least 100 therefore incidents that a cosmetic ingredient is considered as for use.


	Tipo de produto	Preservatives	relative daily exposure default preservatives mg/kg bw/day A	product concentration (%) C	SED (mg/kg bwiday)	NOAEL	MoS (margin of safety)	
	Exfoliating Wash	PHENOXYETHANOL	269	0,25	0,6725	357	590,8550186	
		BENZYL ALCOHOL	269	0,25	0,6725	500	743,4944238	
	Cleansing Mousse	PHENOXYETHANOL	269	0,5	1,345	2.8	2,081784587	1
	Skin Tonic	PHENOXYETHANOL	269	0,25	0,6725	357	530,8550186	1
		BENZYL ALCOHOL	269	0,25	0,6725	500	743,4944238	
SKIN ANTI-AGING	Night cream	BENZYL ALCOHOL	269	0,3	0,807	500	619,5786865	1
PRODUCTS	Eve cream	SODIUM BENZOATE	269	0,5	1,345	1000	743,4944238	
	Eye cream		269	0,4	1,076	357	331,7843866	1
	Serum	BENZYL ALCOHOL	269	0,25	0,6725	500	743,4944238	
	serum	PHENOXYETHANOL	269	0,5	1,345	357	265,4275095	
	AGGREGATE EXPOSURE	BENZYL ALCOHOL	269	1,05	2.8245	500	177.0224819	Mo5 >100
	AGGREGATE EXPOSURE	PHENOXYETHANOL	269	1.9	5.111	357	69.84934455	MoS <100

CONCLUSION

Despite the possible overestimation, aggregate exposure showed to be an efficient tool for the prediction of cumulative risk, allowing to make the best choices of preservative systems during the development of new products. Identification and use of ingredients with lower intrinsic hazard is an important and effective way to reduce overall potential health concerns.


Examples

Development of a human dermal papilla in vitro model



Examples

Mechanistic approach for treating epidermal aging



BM degradation

Adapted from Lorencini et al. Ageing Res Rev. 15, 2014



gente faz

Thank you!

marciolo@grupoboticario.com.br

